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B-cell depletion can improve a variety of chronic inflammatory diseases, but does not
appear beneficial for patients with Crohn’s disease.
Objective
To elucidate the involvement of B cells in Crohn’s disease, we here performed an ‘in depth’
analysis of intestinal and blood B-cells in this chronic inflammatory disease.
Methods
Patients with Crohn’s disease were recruited to study B-cell infiltrates in intestinal biopsies
(n = 5), serum immunoglobulin levels and the phenotype and molecular characteristics of
blood B-cell subsets (n = 21). The effects of infliximab treatment were studied in 9 patients.
Results
Granulomatous tissue showed infiltrates of B lymphocytes rather than Ig-secreting plasma
cells. Circulating transitional B cells and CD21low B cells were elevated. IgM memory B cells
were reduced and natural effector cells showed decreased replication histories and somatic
hypermutation (SHM) levels. In contrast, IgG and IgA memory B cells were normally present
and their Ig gene transcripts carried increased SHM levels. The numbers of transitional and
natural effector cells were normal in patients who responded clinically well to infliximab.
Conclusions
B cells in patients with Crohn’s disease showed signs of chronic stimulation with localization to
granulomatous tissue and increased molecular maturation of IgA and IgG. Therapy with TNFα-
blockers restored the defect in IgMmemory B-cell generation and normalized transitional B-cell
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levels, making these subsets candidate markers for treatment monitoring. Together, these
results suggest a chronic, aberrant B-cell response in patients with Crohn’s disease, which
could be targeted with new therapeutics that specifically regulate B-cell function.
Introduction
The human intestinal tract contains a complex interplay between commensal bacteria, food
antigens and the host immune system to limit inflammation, while preventing the transloca-
tion of intestinal microbiota. This delicate balance is disrupted in Crohn’s disease, a chronic
inflammatory disease characterized by transmural inflammation of the gastrointestinal tract
[1]. The pathogenesis of Crohn’s disease is of complex nature with genetic susceptibility and
dysfunction of mucosal immunity that result in a disturbed intestinal balance [2]. An abnormal
Th1 response is induced by dendritic cells that present commensal bacteria [3], which leads to
overproduction of pro-inflammatory cytokines, including interferon-γ (IFN-γ) and tumor
necrosis factor-alpha (TNF-α). In combination with impaired regulatory T cell (Treg) function,
this is thought to lead to persistent inflammation in Crohn’s disease [4].
In about one third of patients, histopathology of biopsy specimens show granulomas; a fea-
ture supporting the diagnosis Crohn’s disease [5, 6]. As early as in the 1980s, a corona of B lym-
phocytes around the granuloma was described [7], which parallels granulomas in patients with
sarcoidosis [8]. Furthermore, similar to patients with sarcoidosis [8–10], patients with Crohn’s
disease show signs of abnormal B-cell responses that include increased numbers of immuno-
globulin (Ig)-secreting cells [11], and serum antibodies against Saccharomyces cerevisiae anti-
bodies (ASCA) and neutrophils (ANCA) [12, 13]. Being good antigen-presenters and cytokine
producers, B cells can regulate T cell responses [14]. Indeed, B-cells were found to affect regula-
tory T cell through production of IL-10 [15]. However, it is not been clarified how B cells influ-
ence disease activity, because studies in murine models have reported ambiguous results,
supporting either a suppressive or exacerbating role in gut inflammation [16–18].
In spite of a potential role of B cells in chronic inflammation, circulating naive B cells and
class-switched memory B cells were found to be normally present in peripheral blood of
patients with Crohn’s disease, whereas IgM memory B cell numbers were reduced [19]. IgM
memory cells consist of two types; IgM-only (CD27+IgM+IgD-) and natural effector B cells
(CD27+IgM+IgD+). While all IgM-only memory B cells originate from germinal center
responses, about one-third of natural effector cells in healthy controls are derived from T-cell
independent responses in the marginal zone of the spleen [20–22].
These contrasting observations did not clarify the exact role of B-cell involvement in
Crohn’s disease. Therefore, we here aimed to elucidate their contribution in Crohn’s disease
through detailed molecular analysis and immunophenotyping in locally inflamed intestinal tis-
sue and in peripheral blood. Moreover, to evaluate candidate B-cell markers for monitoring




Clinical data and blood samples of 30 patients with Crohn’s disease and 28 healthy controls
were collected after written informed consent was obtained (Table 1). In addition, surplus tis-
sue materials from diagnostic colon biopsies of 5 patients were retrospectively analyzed. This
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study was performed according to the Declaration of Helsinki. This study was approved by the
Medical Ethics Committees of Erasmus MC (ethics approval number MEC-2011-060) and
Alfred Hospital (ethics approval number 472/15) and patients were recruited from the Ikazia
Hospital in Rotterdam (The Netherlands) and the Alfred Hospital in Melbourne (VIC,
Australia).
Immunohistochemistry of gut tissue biopsies
Tissue slides were stained with hematoxylin and eosin. Immunohistochemistry was performed
using monoclonal antibodies against CD4 (clone SP35), CD3 (2GV6), CD79a (SP18; all from
Ventana, Tucson, AZ), CD8 (C8/144 B), CD20 (L26), IgG (rabbit polyclonal; all from Dako
Cytomation, Glostrup, Denmark), IgA (rabbit polyclonal, Cell Marque, Rocklin, CA), CD138
(B-A38; IQ Products, Groningen, The Netherlands), and IgM (IgM88; Biogenex, Fremont, CA).





Medication Surgery Granuloma B-cells T-cells NK-cells IgG IgG1 IgG2 IgG3 IgG4 IgA IgA1 IgA2 IgM
1 F 30 0 None No Yes 91 1,200 270 ND ND ND ND ND ND ND ND ND
2 F 25 3 None Yes No 197 1,100 310 ND ND ND ND ND ND ND ND ND
3 M 23 4 None No No 208 1,575 220 ND ND ND ND ND ND ND ND ND
4 M 34 13 5-ASA Yes No 430 1,120 430 6.8 4.8 1.9 0.2 1.0 2.8 2.0 1.4 1.4
5 M 43 10 5-ASA Yes Yes 470 1,620 270 10.1 7.1 3.8 0.9 <0.06 1.7 1.2 0.2 0.7
6 M 63 5 5-ASA Yes No 160 2,190 310 10.0 6.2 4.8 0.8 0.4 4.9 3.6 1.6 0.7
7 M 35 22 None Yes No 90 470 220 9.0 5.2 5.3 0.6 0.1 4.3 2.9 2.4 0.7
8 M 33 2 5-ASA No Yes 220 1,260 190 11.1 8.3 2.7 0.9 0.5 3.6 2.6 0.8 0.5
9 F 22 7 None No No 250 1,110 270 14.9 11.1 4.0 0.8 0.4 2.6 1.8 0.3 2.3
10 F 27 0 5-ASA No Yes 590 1,790 230 9.2 5.7 3.7 0.5 1.2 1.8 1.3 0.3 1.1
11 F 62 21 5-ASA Yes Yes 160 1,090 220 7.8 4.8 3.7 0.5 <0.06 3.4 2.3 1.0 0.6
12 F 26 8 5-ASA No No 260 750 150 10.6 8.2 3.1 0.2 0.2 1.5 1.1 0.4 0.6
13 F 61 11 5-ASA Yes No 210 1,600 160 15.1 13.0 2.5 0.7 0.1 2.1 1.5 0.3 1.6
14 F 48 34 5-ASA Yes Yes 180 1,220 100 8.4 7.3 0.9 0.5 <0.06 2.7 1.8 1.0 0.7
15 M 45 6 5-ASA No No 380 2,060 820 17.3 10.7 8.3 0.4 2.2 5.8 4.3 1.3 0.7
16 F 35 1 None No No 333 1,990 250 10.7 7.1 5.3 0.6 <0.06 0.7 0.5 0.2 1.2
17 F 31 11 None No No 230 3,250 250 9.5 8.5 1.4 0.7 <0.06 1.3 1.0 0.4 1.3
18 F 35 8 None No Yes 350 1,120 180 16.4 12.5 6.0 1.0 0.2 3.3 2.4 0.5 1.4
19 F 41 23 5-ASA Yes No 110 1,330 150 8.8 5.8 4.1 0.4 <0.06 2.5 1.6 1.1 1.2
20 F 53 0 None Yes No 870 2,500 260 6.3 4.3 2.9 0.5 0.1 0.8 0.6 0.3 ND
21 M 39 3 5-ASA No No 680 1,580 660 15.8 13 3.5 0.8 1.1 1.6 1.1 0.4 1.0
22 F 34 14 IFX, 5-ASA No No 240 1,730 160 11.7 9.0 2.5 0.4 0.1 1.4 1.1 0.1 1.3
23 F 51 14 IFX, AZA Yes Yes 150 970 110 8.7 6.8 2.1 0.4 0.1 2.3 1.8 0.2 1.1
24 M 31 4 IFX No No 200 1,130 80 9.0 5.0 4.0 0.7 0.7 2.3 1.7 0.3 0.5
25 M 58 37 IFX, 5-ASA,
AZA
Yes No 200 2,030 30 16.9 13.3 2.8 0.6 0.1 2.6 1.9 0.2 0.9
26 F 48 19 IFX Yes No 370 2,400 780 9.6 5.1 4.4 0.4 <0.06 3.1 2.1 1.4 1.4
27 F 22 4 IFX Yes No 790 1,760 220 ND ND ND ND ND ND ND ND ND
28 F 33 15 IFX, AZA Yes Yes 128 513 21 ND ND ND ND ND ND ND ND ND
29 F 46 9 IFX Yes No 120 460 28 ND ND ND ND ND ND ND ND ND
30 M 22 2 IFX, AZA No No 199 855 22 ND ND ND ND ND ND ND ND ND
Lymphocyte subsets are provided in cells/μL, Immunoglobulin levels in g/L. Abnormal values are depicted in bold font. Deﬁnition of abbreviations: F, female;
M, male 5-ASA, 5-aminosalicylic acid; IFX, inﬂiximab; AZA, azathioprine. Normal values: B cells: 100–400 cells/μl; T cells: 700–1900 cells/μl; NK cells; 100–
400 cells/μl; IgG: 7–16 g/L; IgG1: 4.9–11.4 g/L; IgG2: 1.50–6.4 g/L; IgG3: 0.20–1.10 g/L; IgG4: 0.080–1.40 g/L; IgA: 0.70–4.0 g/L; IgA1: 0.6–2.4 g/L; IgA2:
0.1–0.6 g/L; IgM 0.4–2.3 g/L.
doi:10.1371/journal.pone.0160103.t001
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Flowcytometry and cell sorting of blood lymphocytes
Absolute counts of blood CD4 and CD8 T cells, CD16+/56+ natural killer cells, and CD19+ B
cells were obtained with a diagnostic lyse-no-wash protocol. Eight-color flow cytometric analysis
was performed as described previously to detect transitional, naive mature, six memory B cell
subsets, plasmablasts and CD21lowCD38dim cells (S1 Fig) on a 3-laser FACS LSRII with standard-
ized configuration according to Euroflow protocols (BD Biosciences, San Jose, CA) [23]. Detailed
analysis of B cell subsets was performed with IgM-HorV450 (G20-127; BD), IgD-biotin (IA6-2),
IgG-PE (G18-145), CD19-PE-Cy7 (SJ25C1), CD19-PerCP-Cy5.5 (SJ25C1), CD21-PE-Cy7 (B-
ly4), CD27-PerCP-Cy5.5 (L128), CD27-APC (L128), CD38-APC-H7 (HB7; all from BD Biosci-
ences, San Jose, CA, USA) and IgA-FITC (IS11-8E10; Miltenyi-Biotec GmbH, Germany) [24].
Biotinylated antibodies were visualized with streptavidin-Pac.Orange (Invitrogen).
Naive mature and natural effector B cells were high-speed cell sorted to greater than 95%
purity on a FACSAria I (BD Biosciences), as described previously [25].
Quantification of serum immunoglobulin levels
Serum IgM, IgG, and IgA levels were measured with an immunoturbidimetric method (Hitachi
Analyzer; Roche, Basel, Switzerland). IgG and IgA subclasses were determined using the
immunonephelometric method (Sanquin, Amsterdam, The Netherlands).
Molecular analysis of replication history and immunoglobulin heavy
chain (IGH) transcripts
IGHA and IGHG transcripts were amplified from PBMC cDNA of patients with Crohn’s dis-
ease (n = 4) and healthy controls (n = 4). IGHV3 and IGHV4 leader primers and consensus Cα
or Cγ reverse primers were used [22].
DNA was isolated from sorted naive mature and natural effector B cells of patients with
Crohn’s disease (n = 4) to analyze the replication history with the kappa-deleting recombina-
tion excision circle assay as described previously [25]. In addition, IGH gene rearrangements
were amplified from DNA of sorted natural effector B cells. PCR products were cloned into the
pGEM-T easy vector (Promega, Madison, WI) and prepared for sequencing on an ABIPRISM
3130XL (Applied Biosystems, Carlsbad, CA). Obtained sequences were analyzed with IMGT
database (http://imgt.cines.fr), Joinsolver (https://joinsolver.niaid.nih.gov) and Bayesian esti-
mation of Antigen-driven SELectIoN (BASELINe; http://selection.med.yale.edu/baseline/). IgA
and IgG receptor subclasses were determined using the IGH reference sequence (NG_001019).
Statistics
Statistical analyses were performed using the Mann-Whitney test (SPSS version 18.0), χ2 test
or Spearman correlation as indicated in Figure legends. A P-value<0.05 was considered statis-
tically significant.
Results
Clinical and basic immunological characterization of patients
In this study, 30 patients with biopsy-confirmed Crohn’s disease (11 males) were included with
a mean age of 38.5 yr (range 22–62 yr; Table 1). Patients 1–21 had not received immunosup-
pressive drugs for at least three months prior to inclusion. Of these 21 patients, 12 patients
received 5-ASA medication, 9 were without any medication for Crohn’s disease and 11/21
patients had received systemic immunosuppressive medication in the past. All patients had
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clinically mild to moderate disease without a need for systemic immune suppressive treatment
at the time of study inclusion. Patients 22–30 received infliximab treatment for>6 weeks at
study inclusion and were clinically good responders. In 9/30 patients, granulomas were previ-
ously detected in ileal or colon biopsies and 16/30 patients had a history of surgical resection of
the gut. The average duration of disease at study inclusion was 10.3 years (range 0–34 year).
Mean values of B, T and NK cells, as well as mean serum IgM, IgG and IgA levels were within
the normal range. The average IgA2 serum level of the patients was increased as compared to
controls (0.7 g/L; range 0.1–2.4; normal range 0.1–0.6), with 9/23 patients having levels above
the normal range.
B cell localization around granulomas
All colon tissue biopsies showed inflammation compatible with Crohn’s disease. Haematoxylin
and eosin-staining of the granulomas did not show any sign of necrosis. T cells were easily
detectable with stainings for CD3, CD4 or CD8, and were located throughout the inflamed tis-
sue, both inside and outside the granulomas (Fig 1). In agreement with previous observations
[7], CD4+ T cells were more numerous than CD8+ T cells with a ratio of 4:1. CD20+ B cells
were detectable in intestinal biopsies, but these were restricted to normal lymphoid follicles
and were very sparse in the non-granulomatous inflamed tissue (Fig 1). However, directly sur-
rounding the granulomas, B cells were numerous as visualized with CD20 or CD79a stainings
(Fig 1). Plasma cells are abundantly present in the human gut tissue of healthy individuals,
with IgA as their major product [26, 27]. Tissue sections from our patients with Crohn’s disease
showed numerous CD138+ plasma cells, both in inflamed and in non-inflamed regions. These
plasma cells were not specifically localized near granulomas, but were distributed over the gut
tissue with the majority secreting IgA and smaller fractions IgG or IgM (S2 Fig). The specific
localization of B cells surrounding granulomas indicates involvement of B cells in the immuno-
pathogenesis of granulomatous inflammation in Crohn’s disease.
Fig 1. B-cells accumulate around granulomas in affected colon tissue in Crohn’s disease. A, Representative
images of colon biopsies with granulomas and non-granulomatous tissue in two patients with Crohn’s disease. B,
Magnifications of granulomatous tissue from panel A.
doi:10.1371/journal.pone.0160103.g001
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Abnormalities in blood B cell subsets in patients with Crohn’s disease
To study whether local intestinal inflammation affected B cells systemically, we studied blood
B-cell subsets in 21 patients with Crohn’s disease. Flowcytometric analysis revealed normal
numbers of total CD19+ B-cells in patients (n = 21) as compared with healthy controls
(n = 28). Further subsetting of these CD19+ B cells (Fig 2A) revealed significantly increased
numbers of CD38highCD24high transitional B cells (P = 0.009), while CD27-IgD+ naive mature
B cells were normally present (Fig 2B). Within the antigen-experienced B-cell compartment,
IgM+ memory B cells were low with CD27+IgM+IgD+ natural effector B cells being significantly
decreased (P<0.001), IgM-only B cells (CD27+IgM+IgD-) not-significantly decreased
(P = 0.06). The numbers of class-switched B cell subsets (CD27+IgG+, CD27-IgG+, CD27+IgA+
and CD27-IgA+) and plasma blasts were similar between patients and controls. Large fractions
of the patients’ B cells showed low CD21 expression levels and these numbers were significantly
higher than in healthy controls (P<0.0001). The increase was not related to disease duration
(P = 0.10; Fig 2D), and a large fraction of these CD21low B cells were Ig class switched to IgA or
IgG, suggestive of an origin from antigen-experienced B cells (Fig 2C).
To study whether the abnormalities in transitional, natural effector and CD21low B cells
were associated with surgical treatment and current or past medication, additional analyses
were performed following division of the total 21 patients into patients with (n = 10) or without
surgical resection (n = 11), into patients currently treated with (n = 12) or without 5-ASA med-
ication (n = 9) and patients with (n = 11) and without (n = 10) a history of systemic medica-
tion. All three analyses revealed similar patterns for the separate patient groups (S3 Fig),
thereby excluding differential effects of these treatments on the blood B-cell compartment.
Fig 2. Composition of the blood B-cell compartment in patients with Crohn’s disease. A. Schematic overview of peripheral B-cell subsets. B. Average
numbers of blood B cell subsets of 21 patients affected with Crohn’s disease (black bars) and 28 healthy controls (light grey bars). C. Distribution of IgM, IgA
and IgG within CD21low in patients and controlsD. Total CD21low B cells in relation to disease duration. Statistical analyses were performed with the Mann-
Whitney test or Spearman correlation; *, P<0.05; **, P<0.01.
doi:10.1371/journal.pone.0160103.g002
B-Cell Abnormalities in Crohn's Disease
PLOS ONE | DOI:10.1371/journal.pone.0160103 July 28, 2016 6 / 15
Impaired generation of natural effector B cells
Our flowcytometric analysis showed decreased numbers of natural effector B cells in peripheral
blood of patients with Crohn’s disease, line with previous findings [19]. To study whether the
decline was due to impaired generation of these cells, we analyzed the replication history and
somatic hypermutation (SHM) levels in purified cells from four patients (Patient 15, 16, 18 and
19). Naive mature B cells of patients and controls showed a similar replication history of 1–2
cell divisions [25]. However, the patients’ natural effector B cells showed a replication history
of only 2 cell division versus 9 in controls (P = 0.002; Fig 3A). These natural effector B cells car-
ried diverse IGH gene rearrangements, with shorter IGH-CDR3 sizes than in naive B cells,
which is a typical feature of antigen-experienced B cells (Fig 3D) [22]. Still, the majority of rear-
rangements amplified from the patients carried unmutated IGHV genes (28 of 51 unique rear-
ranged IGHV). Moreover, the overall SHM levels were significantly lower than in controls
(P<0.0001; Fig 3B), and hardly higher than in naive mature B cells. The few mutations in
patients’ Ig genes were normally targeted (S1 Table). However, on top of their low numbers,
the mutations in complementarity determining regions (CDR) were not selected for amino
acid replacements as is typical seen in healthy controls (P<0.0001; Fig 3C). Thus, IgM+IgD+-
expressing memory B cells in patients with Crohn’s disease are not only decreased in number,
they also display a defects in replication history and SHM.
Increased SHM levels in Ig genes of switched memory B cells
In contrast to IgM+ memory B cells, Ig class-switched memory B cells were normally present in
blood of patients with Crohn’s disease (Fig 2) [19]. Their IgA and IgG transcripts displayed a
diverse usage of IGHV3 and IGHV4 subgroups with CDR3 size distributions similar to those of
controls and typical for antigen-experienced B cells with a median of 15 amino acids (S5 Fig).
These transcripts showed high levels of SHM, which appeared to be normally targeted to the
typical sequence motifs (S1 Table). In addition, nucleotide substitution spectra and transition/
transversion ratios did not differ between patients and controls. To determine whether these
transcripts showed signs of antigen selection, we analyzed selection for replacement mutations
using the BASELINE program. Similar to healthy controls, sequences derived from patients
with Crohn’s disease showed positive selection for replacement mutations in CDR and negative
selection in framework regions (FR) (S5C Fig).
Fig 3. Replication history and SHM levels in IGHV genes of natural effector B cells. A, Replication history of naïve and natural effector B cells
as assessed using the KREC assay [25]. B, IGHVmutation frequencies in rearranged IGH genes of natural effector B cells in patients and controls
(total numbers of sequences indicated between brackets). Grey dots represent unique sequences; red lines represent median values.C, Selection
for replacement mutation in IGHV-CDR (red line) and IGHV-FR regions (blue lines) as determined with the BASELINe program [28, 29]. Solid lines
represent patients; dashed lines represent healthy controls. Selection Strengths >0 indicate positive selection.D, IGH-CDR3 size distributions. All
individual sizes are indicated as grey dots, red lines representing median values. The dashed line represents median values for centroblasts and
centrocytes. Sorted cells were analyzed from patients 15, 16, 18 and 19. Controls were published previously [30, 31]. Statistical analysis was
performed with the Mann-Whitney test; *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.
doi:10.1371/journal.pone.0160103.g003
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To study whether the high SHM levels were the result of altered IgG and IgA subclass usage,
we analyzed these in the rearranged transcripts [32, 33]. Patients with Crohn’s disease showed
increased IgA1 and IgG2 usage, to the expense of IgA2 and IgG3 (Fig 4B). Still, these altered
distributions did not underlie the difference in SHM levels. IgA1 and IgA2, as well as IgG1 and
IgG2 transcripts of the patients carried more SHM than those of controls (Fig 4C). More spe-
cifically, a substantial fraction of IgA2 transcripts from controls was hardly mutated, and this
fraction was nearly absent in patients with Crohn’s disease. In conclusion, patients with
Crohn’s disease show increased levels of SHM with otherwise normal targeting and selection
for replacement mutations. This was independent of the concomitant reduction in IgA2 and
IgG3 subclass usage.
Normalization of blood B-cell subsets in infliximab-treated patients
Previous observations indicated normalization of spleen function and levels of circulating IgM
+ memory B cells in Crohn’s disease patients following infliximab therapy [34]. To study
whether successful treatment normalized the total peripheral B-cell compartment, we pheno-
typed blood B cells in 9 patients that were receiving infliximab (patients 21–30; Table 1).
Fig 4. IgA and IgG subclass analysis. A, Schematic representation of the constant region of the human IGH locus.B, Distribution of IgA and IgG subclass
use in switched transcripts of healthy controls and patients with Crohn’s disease. Total numbers of analyzed sequences are indicated in the middle of the
plots. χ2 Test was performed to analyze differences in distributions. C, Combined IGHVmutation frequencies in IgA and IgG transcripts in patients and
controls (total numbers of sequences indicated between brackets). Grey dots represent unique sequences; red lines represent median values. Statistical
analysis was performed with the Mann-Whitney test; *, P<0.05; **, P<0.01; ***, P<0.001.
doi:10.1371/journal.pone.0160103.g004
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Infliximab was administered once every eight weeks for a long period of time (range 8 months-
10 years), and all patients were in clinical response after treatment. In contrast to patients not
receiving infliximab, transitional B cells and natural effector B cells were normalized to levels
comparable with healthy controls (Fig 5A). However, IgM-only B cell numbers were still low,
and CD21low B cells remained increased as compared to healthy controls. Within CD21low,
the IgM, IgA and the IgG expressing subsets were higher in number than in healthy controls.
Patients treated with infliximab showed a further increase in the IgA subset, with an accompa-
nied (non-significant) decrease in IgM (Fig 5B). A substantial fraction of the CD21low subset
expressed CD27, and CD27+ and CD27- was similar between controls and patients (S4A Fig).
In absolute numbers, both fractions were elevated in patients. Thus, patients with Crohn’s dis-
ease show systemic abnormalities in their B cell compartments, which appear almost
completely recovered by successful infliximab treatment.
Fig 5. Effects of infliximab on blood B-cell and CD21low compartment. A, Blood B-cell compartments in patients under treatment with infliximab. B,
Absolute total numbers of IgM, IgA and IgG with low CD21 expression in controls, patients and patients under treatment with infliximab. Bars represent
mean values ±SEM. Statistical analysis was performed with the Mann-Whitney test; *, P<0.05; **, P<0.01; ***, P<0.001.
doi:10.1371/journal.pone.0160103.g005
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Discussion
In this study, we demonstrate that patients with Crohn’s disease have an infiltration of B cells
around granulomas and an altered B-cell compartment in the peripheral blood. While IgM
memory B-cell formation was impaired, Ig class switched B cells showed molecular sings of
chronic stimulation. Importantly, alterations in the peripheral B-cell compartment normalized
after treating inflammation effectively with TNFα-blockers.
Our findings of B cells surrounding granulomas in Crohn’s disease extend previous observa-
tions from the 1980s [7], and more recent ones from pediatric patients with Crohn’s disease
with NOD2 gene mutations [35]. These B cells appear to be lymphocytes and not plasma cells
and localize specifically around the granulomas. Still, the origin and types of B cell subsets
remain unclear. Large amounts of B cells were also found to be present around the granulomas
in sarcoidosis [8], and consequently researchers have evaluated treatment with anti-CD20 ther-
apy (e.g. with rituximab) [36]. It is possible that these B cells are crucial for the formation of
granulomas. This is supported by studies in mouse models that were capable of granuloma for-
mation in the absence of T cells, but not in the absence of B cells [37]. Furthermore, granulo-
mas are found in a large fraction of patients with antibody deficiencies in the presence of B
cells (esp. Common Variable Immunodeficiency; CVID), while these have not been reported in
patients with X-linked agammaglobulinemia, who lack circulating B cells due to a block in dif-
ferentiation of precursor B cells [38]. How these B cells would function in the formation of
granulomas remains unclear. B-cell depletion therapy seems to induce and exacerbate colitis
[39, 40], while immunoglobulin substitution can induce rapid dampening of inflammation in
patients with Crohn’s disease [41]. Thus, it is well-possible that the local B cells have a regula-
tory function to control inflammation [42].
Our patients showed alterations in blood B cell subsets in absence of systemic immunosup-
pressive therapy. One of these was a strong reduction in circulating IgM+memory B cells, which
was the result of impaired generation rather than increased loss, because the few remaining IgM
memory ‘natural effector’ B cells showed severely reduced replication history, SHM levels and
absence of selection for replacement mutations in CDR. The loss of IgMmemory B cells was pre-
viously attributed to impaired spleen function [19]. However, a large fraction of these ‘natural
effector’ B cells is dependent on T-cell help and more likely originates from germinal center reac-
tions [21, 22]. Considering the strongly decreased natural effector B-cell numbers in our patients,
it is therefore likely that in addition to IgM responses in the spleen, also germinal center responses
are impaired in the generation of IgM+ memory B cells in patients with Crohn’s disease.
In contrast to IgM+ memory, transitional and CD21low B-cell numbers were increased in
our patients. Higher numbers of transitional cells were previously observed in patients with
other chronic inflammatory diseases, including sarcoidosis and SLE [8, 9, 43]. This increase
could reflect increased B-cell output from the bone marrow. Still, this did not result in higher
numbers of circulating mature B cells and might be due to inability of these transitional B cells
to further mature. CD21low B cells are peculiar cells that have been described to be functionally
anergic with the downregulation of CD21 suppressing their responsiveness and decreasing
their survival [22, 44]. The increase in transitional B cells could therefore be a compensation
for the loss of mature B cells through downregulation of CD21. While CD21low B cells are
scarce in healthy controls, their numbers are increased during infections, autoimmune diseases
[22, 45, 46], CVID with autoimmunity and Down syndrome [44, 46–48]. As these cells were
not increased in patients with sarcoidosis [8], CD21low B cells could represent a marker of dis-
tinct pathophysiology between these two granulomatous inflammatory diseases.
The numbers of natural effector B cells normalized under infliximab therapy, an observa-
tion that was made previously as well and was associated with restoration of spleen function
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[34]. More recently, Li and colleagues also confirmed these low numbers of pre-switched mem-
ory B cells in inflammatory bowel disease and its restoration with TNFα-blockers [49]. Thus,
infliximab therapy either directly or indirectly by dampening inflammation restores IgM mem-
ory in patients with Crohn’s disease. Whether natural effector B cells can predict successful
therapeutic outcome would need to be investigated in future studies with longitudinal follow-
up of patients. Treatment with 5-ASA did not show this effect on the B-cell compartment. This
could be due to the difference in therapeutic mechanisms or the merely local application of
5-ASA medication in contrast to systemic effects of infliximab. Alternatively, infliximab can
induce and maintain mucosal healing [50]. Furthermore, the CD21low population was the aber-
rant B-cell subset in our patient group that did not normalize during treatment with infliximab,
suggesting that the process to downregulate CD21 is either not affected by TNFα-blockers, or
is maintained to dampen inflammation.
A large fraction of CD21low B cells was Ig class switched, suggesting their origin from mem-
ory B cells. Indeed, the increased SHM levels in IgA and IgG transcripts reflected abnormally
high or strong activation of these class-switched memory cells. SHM levels are tightly regulated
and even in individuals continuously exposed to parasites these are not increased [32, 33].
Notably, IgA transcripts in patients with Crohn’s disease were highly mutated, and the fre-
quencies of hypomutated transcripts were lower than in healthy controls. A substantial fraction
of blood IgA+ memory B cells carries polyreactive immunoglobulins. These are typically highly
mutated and bind strongly to mucosa-colonizing bacteria [51]. Despite the high SHM levels,
the Ig transcripts from patients with Crohn’s disease did not show signs of additional selection
for replacement mutations in CDR regions. This is suggestive of a lack in additional affinity
maturation, and the result of abnormal and chronic activation in patients with Crohn’s disease
and in previously studied sarcoidosis patients [8]. Despite the signs of chronic stimulation,
total numbers of IgA and IgG memory B cells were not increased in blood of patients with
Crohn’s disease. This is potentially due to their infiltration into tissue. Alternatively, these cells
could be silenced by downregulating CD21 expression. This would make the cells more suscep-
tible to cell death and would explain, at least in part, the expansion of the CD21low B cell
population.
Conclusion
Our study demonstrates distinct B-cell maturation alterations in both local inflamed tissue and
in peripheral blood of patients with Crohn’s disease. These effects were independent of 5-ASA
treatment or past systemic therapy and surgical resections, and seemed homogeneous in our
study population. Especially the Ig class-switched B cells show signs of chronic stimulation,
while the generation of IgM memory B cells is impaired. Moreover, clinical improvement is
heralded by normalization of the elevated circulating transitional and natural effector B cells in
response to TNFα-blockers. Thus, through dissection of the local and systemic B cell compart-
ments, this study provides new insights into their role in chronic inflammation. Specifically,
blood B-cell deviations could represent good markers to predict treatment success before or
early after start of infliximab or other novel therapeutics in Crohn’s disease.
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S1 Fig. Flowcytometric gating strategy for B-cell subsets in a representative healthy control
(A) and a patient with Crohn’s disease (B). B cells defined as CD19+ lymphocytes and further
subsetted into two naive subsets (transitional cells and naive mature cells), six memory subsets,
plasma cells and CD38dimC21low cells. Non-switched memory B cells were separated into natu-
ral effector (CD27+IgM+IgD+) and IgM-only cells (CD27+IgM+IgD-). IgA and IgG switched
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memory B cells were further separated into CD27- and CD27+ subsets.
(EPS)
S2 Fig. Immunohistological analysis of plasma cells in sections with (A) and without gran-
ulomas (B) in colon biopsies of two patients with Crohn’s disease. Both tissues show pres-
ence of CD138+ plasma cells, with the majority producing IgA, to a lesser extent IgG and low
frequencies IgM.
(TIF)
S3 Fig. Blood B-cell compartments in (A) patients with a history of resection, (B) patients
under treatment with 5-ASA medication, and (C) patients with a history of systemic immu-
nosuppressive medication. Bars represent mean values ±SEM. No significant differences were
found for any subset between Crohn’s patients with or with the indicated mode of treatment
(Mann-Whitney U test).
(EPS)
S4 Fig. CD21low population in controls, patients on infliximab and Crohn’s disease patients
without systemic treatment. A, Relative distribution of CD27- and CD27+ cells within the
CD21low compartment. B, Absolute cell counts of CD27- and CD27+ cells within CD21low
compartment. Bars represent mean values ±SEM.
(EPS)
S5 Fig. Somatic hypermutation analysis of IgM, IgA and IgG B cells. Somatic hypermuta-
tion levels in IGHV genes of rearranged IgA (A) and IgG (B) transcripts of four patients
with Crohn’s disease and four healthy controls. Grey dots represent unique sequences; red
lines represent median values. C, Selection for replacement mutation in IGHV-CDR (red line)
and IGHV-FR regions (blue lines) as determined with the BASELINe program [28, 29]. Solid
lines represent patients; dashed lines represent healthy controls. Selection Strengths>0 indi-
cate positive selection.D, IGH-CDR3 size distributions. All individual sizes are indicated as
grey dots, red lines representing median values. The dashed line represents median values for
centroblasts and centrocytes from controls (22).
(EPS)
S1 Table. Targeting and selection of individual mutations in rearranged IGHV.
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